Author Archives: mmcdonald

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14^th through September 16^th, 2026 in New York City.

Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link.

Event Details:

• Conference: 28th Annual H.C. Wainwright Global Investment Conference

• Date: September 14-16th, 2026

Accredited investors interested in scheduling a meeting with the Lexaria management team should contact their H.C. Wainwright representative or email [email protected].

About Lexaria Bioscience Corp. & DehydraTECH^TM

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH^TM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate

KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Lexaria strategically performed its previous 12-week chronic GLP-1-H24-4 Study in Australia, fully aware of certain potential tax advantages in doing so. Lexaria's 2025 application for the cash rebate was accepted after a review that verified its compliance with the Australian Research & Development ("R&D") Tax Incentive Program. The payment has now been received and confirmed. Lexaria intends to use these proceeds for future R&D plans in Australia aimed at further validating its technology.

"This is USD$2.6 million dollars received without having to issue any equity and thus avoiding shareholder dilution related to these funds," said Richard Christopher, CEO of Lexaria Bioscience Corp. "Together with our recently announced new pharmaceutical partnership and exciting Animal Study #2 pharmacokinetic results, Lexaria continues to leverage and demonstrate its R&D capabilities in every way possible."

Of note, the USD$2.6 million rebate has not been included in Lexaria's previously filed financial statements or cash runway projections; however, now that the receipt of the rebate has occurred, it will be accounted for in the Company's upcoming annual 10-K filing.

In the months to come, Lexaria expects to announce its 2027 R&D plans that will, among other things, utilize these newly-received funds. Lexaria remains completely debt-free as it responsibly continues to pursue as many business development opportunities as possible through applied R&D supporting its DehydraTECH technology.

About Lexaria Bioscience Corp. & DehydraTECH^TM

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH^TM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

• Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study

• Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated

• Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs

KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycretin and retatrutide, in a total of 18 different study arms in dogs following formulation and processing using Lexaria's patented DehydraTECH^TM ("DHT") drug delivery enabling platform technology formulated in oral tablet and capsule formats.

The Study utilized both Lexaria's DehydraTECH-GLP-1 2.0 ("DHT2.0") formulation tested against Lexaria's new DehydraTECH-GLP-1 3.0 ("DHT3.0") formulations together with potentially complementary commercially available gastrointestinal absorption enhancer compounds; salcaprozate sodium ("SNAC") or sodium caprate. Lexaria is testing DHT3.0 formulations in anticipation of supporting existing and future business development initiatives for the next generation of GLP-1 drugs under development around the world.

"Lexaria never stops innovating in our pursuit of the most effective oral drug delivery possible," said Richard Christopher, CEO of Lexaria. "Not only are our latest enhancements producing clear improvements in performance over earlier versions of DehydraTECH, but those improvements demonstrate our rapidly growing understanding of the interactions between DehydraTECH and the next generation of GLP-1 drugs."

AMYCRETIN

AUC D = Dose normalized area under the curve, or total drug absorption measured over the course of the Study relative to the dose administered.

N/A = Not applicable because the REF DHT2.0 Capsule did not provide meaningful absorption data.

All data has been rounded to 2 decimal points for consistency and ease of presentation.

Lexaria's DHT3.0-amycretin tablet ("ALT 2 DHT3.0 Tablet") was the strongest DHT performer tested evidencing a 481.14% increase in bioavailability compared to the amycretin reference tablet ("REF DHT2.0 Tablet") that used DHT2.0 and SNAC. The patented DHT3.0 technology performed better with the 'open source' sodium caprate than it did with the SNAC technology currently used in Novo Nordisk's® oral Rybelsus® and Wegovy® tablet products.

All 3 of the DHT3.0-amycretin tablet variations achieved superior absorption than the amycretin reference tablet ("REF DHT2.0 Tablet") that used DHT2.0 and SNAC. Lexaria considers these improvements in DHT3.0 performance to be deeply meaningful relative to our ultimate goal of attracting widespread adoption of DHT technology within the multi-billion-dollar GLP-1 sector and its next-generation drugs. If confirmed with further testing including human studies, DHT3.0 GLP-1 formulations could eventually be of interest to pharmaceutical companies working towards adoption of their own proprietary weight loss drugs.

Lexaria's best performing DHT-amycretin tablet formulation ("ALT 2 DHT3.0 Tablet"), rendered in a 4 mg oral tablet format, evidenced a 136%, or more than double, increase in absolute bioavailability (1.65%) compared to animal research published by Novo Nordisk A/S that indicated an absolute bioavailability level of 0.70% for its SNAC-inclusive orally administered amycretin at comparable dosing, but without DHT, in primates. Lexaria acknowledges, however, that inter-species variability between the two different studies likely contributed to some unknown degree to the difference in those outcomes.

The amycretin reference capsule ("REF DHT2.0 Capsule") did not provide meaningful absorption data relative to the lower limit of detection of the bioassay utilized for this Study, so no comparisons can be made between it and the DHT3.0 capsule variations in the Study.

RETATRUTIDE

All 3 of the 3 experimental DHT3.0-retatrutide capsule formulations, and all 3 of the 3 experimental DHT3.0-retatrutide tablet formulations, outperformed the respective retatrutide reference capsules and tablets enabled with DHT2.0 and SNAC.

AUC D = Dose normalized area under the curve, or total drug absorption measured over the course of the Study relative to the dose administered.

All data has been rounded to 2 decimal points for consistency and ease of presentation.

The 3 various DHT3.0-retatrutide tablet formulations showed astonishing improvements in absorption of roughly 5x to 46x that of the reference tablets ("REF DHT2.0 Tablet"), which was highlighted by an astonishing 4,552.20% improvement in absorption in the best performing DHT-retatrutide tablet formulation ("ALT 2 DHT3.0 Tablet") as compared to the retatrutide reference tablets ("REF DHT2.0 Tablet"). Consistent with the amycretin results in the Study, retatrutide with the patented DHT3.0 technology performed better with the 'open source' sodium caprate than it did with the SNAC technology currently used in Novo Nordisk's® oral Rybelsus® and Wegovy® tablet products. It is not known at this time whether these improvements are a function of the relatively low absorption of the retatrutide reference tablets, or are indeed representative of reproducible results. Taken at face value, the significant improvements in absorption utilizing DHT3.0 processing and formulation improvements certainly suggest that an oral version of the presently injection-only drug retatrutide may indeed be possible, although extensive human studies would be required to fully validate this.

Bioanalytical testing with the best performing DHT3.0-retatrutide capsule formulations ("ALT 1 DHT3.0 Capsule" and "ALT 2 DHT3.0 Capsule") in the Study, rendered in a 7 mg oral capsule format, demonstrated absolute bioavailability at 0.26% relative to intravenously administered retatrutide ("Pure API (I.V.))". Lexaria has been unable to source any published scientific literature for comparison purposes for other oral developmental formulations of retatrutide and notes that absolute bioavailability of the only commercially available, oral GLP-1 peptide, semaglutide, can be as low as 0.33-0.63% in dogs in published animal study findings at similar dosing levels, or as low as 0.4-1.0% in its initially launched Rybelsus® "R1" composition in humans. Retatrutide, however, lacks similar published references. Relatively speaking, Lexaria's DehydraTECH-retatrutide oral absolute bioavailability finding of 0.26% appears to show directional positivity worthy of further research and development enhancement and exploration.

About the Study and Absolute Bioavailability

The primary goals of this Study were to investigate compatibility of amycretin and retatrutide with Lexaria's DHT-3.0 formulation and processing technology together with certain potentially complementary commercially available gastrointestinal absorption enhancer compounds, centered around PK performance and tolerability. Blood samples were taken at multiple timepoints over a 24-hour post-dosing period to quantify the PK performance of each composition. There were a total of 9 study arms for each of amycretin and retatrutide, including 1 intravenous arm each to provide 100% absolute bioavailability benchmarks; as well as 1 reference DHT2.0 tablet and 1 reference DHT2.0 capsule for each of the drugs: allowing for 3 experimental DHT3.0 capsule and 3 experimental DHT3.0 tablet-related arms for each drug.

Absolute bioavailability is the fraction of an active drug substance that reaches the systemic circulation following non-intravenous administration compared to an intravenous given dose. This figure is noteworthy particularly when compared to available published scientific literature.

As in Animal Study #1 (GLP-1-A26-1) announced on April 15th, this Study also evaluated alternative DHT formulations to those previously explored or commercially available. The present Study included 1 capsule and 1 tablet composition for each of amycretin and retatrutide using sodium caprate which has itself been shown to influence gastrointestinal absorption.

Retatrutide is owned by Eli Lilly and Company®, whereas amycretin is owned by Novo Nordisk®, and are two of the most powerful, next generation GLP-1 peptide drugs under pre-commercial development in the world today, presently in advanced clinical testing only in injectable formats despite increasing consumer interest and demand for oral GLP-1 therapies.

Additional Study information including tolerability and other data will be released in due course upon completion of all relevant analysis and reporting. This was a self-sponsored Lexaria Study that was fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH^TM

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH^TM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.

The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1 molecule which will then be processed with Lexaria's patented DehydraTECH technology and evaluated for pharmacokinetic performance in animal studies.

"We welcome PegBio to our expanding group of potential future commercial partners for DehydraTECH-powered GLP-1 drugs," said Richard Christoper, CEO of Lexaria Bioscience Corp. "PegBio has built an impressive group of GLP-1-related drug products and candidates focused on type-2 diabetes, weight loss, and MASH*. Lexaria is excited that our proprietary technology may assist in making their drugs as accessible and effective as possible."

PegBio's leading product is a GLP-1 molecule that was approved for use in China, administered via injection, in November, 2025. In addition, they have several other molecules that have advanced from preclinical stage up to Phase II, both in China and in the USA.

Lexaria was introduced to PegBio through Liberi Group, a global life sciences business development consultancy working with Lexaria on its DehydraTECH partnering strategy.

Lexaria will provide an update upon the completion of the contemplated study(ies) including whether any business decisions have been made at that time, regarding technology licensing or other business.

*metabolic dysfunction-associated steatohepatitis

About PegBio

PegBio is a biotechnology company focused on the discovery, development and commercialization of innovative therapies for metabolic and related chronic diseases. Its first internally developed innovative drug, the long-acting GLP-1 receptor agonist PB-119 (Visepegenatide Injection), was approved in China in November 2025 and has entered commercialization.

Building on its commercial-stage product, PegBio is advancing a pipeline of differentiated next-generation therapies for diabetes, obesity and other metabolic diseases, while developing a next-generation intelligent R&D and data platform integrating artificial intelligence, computational science and biotechnology. PegBio is listed on The Stock Exchange of Hong Kong Limited (HKG:2565).

For more information, please visit pegbio.com.

About Lexaria Bioscience Corp. & DehydraTECH™

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

About Liberi Group

Liberi Group is a global business development and strategic consultancy focused on the life sciences and biotech industries. The firm partners with innovative biotech and pharmaceutical companies to identify, structure, and advance strategic partnerships, licensing agreements, and investor relationships across global markets. Liberi Group combines deep scientific understanding with an extensive network of industry relationships to connect promising technologies with the right partners at the right time. This collaboration between Lexaria and PegBio reflects Liberi Group's ongoing work supporting Lexaria's DehydraTECH partnering strategy. For more information, please visit Global Life Science Consulting.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the "Reverse Split").

The primary goal of the Reverse Split is to increase the per Share market price of the Company's Shares with the objective of regaining compliance with the NASDAQ Capital Market's ("Nasdaq") minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) (the "Minimum Price Rule"). The Reverse Split is also being performed in an effort to stabilize uncertain stock conditions in the face of a number of critical business drivers which we believe to be in the best immediate and long-term interests of our shareholders.

"The Reverse Split is a critical step towards our continued listing on Nasdaq," stated Richard Christopher, CEO of Lexaria Bioscience Corp. "We have determined that it is prudent and extremely important that the Reverse Split is conducted sooner rather than later," continued Mr. Christopher. "Nasdaq compliance is impactful to Lexaria on so many levels including our ability to attract new business development partners, advance existing business development discussions, and broaden our overall investor appeal. Recent equity market weakness is at odds with the great potential of our technology, and the Company needs a stable foundation in order to take advantage of existing and upcoming opportunities."

The Reverse Split will be conducted on a 1-for-15 basis resulting in the Company's current issued share capital of 24,787,446 shares of common stock ("Shares") being consolidated into 1,652,518 Shares, subject to further adjustment for fractional Shares which will be rounded up to the nearest whole number. In addition, the Company's number of authorized shares and issued convertible securities (options and warrants) will also be subject to the Reverse Split, with the exercise prices of the Company's outstanding convertible securities being adjusted accordingly. In arriving at the Reverse Split ratio, the Company also examined 24 other reverse stock splits conducted by Nasdaq listed biotech companies from January 1 to June 30, 2026, wherein the average reverse split ratio was 1-for-18.

In proactively performing this Reverse Split contemporaneous with the end of our 180-day compliance period we anticipate requesting the required Nasdaq hearing to appeal any delisting notification, and we expect to comply with the Minimum Price Rule in mid-August before any such hearing takes place.

The Shares issued pursuant to the Reverse Split will remain fully paid and non-assessable. The Reverse Split will also consolidate the number of authorized Shares from 220,000,000 authorized to 14,666,667 authorized but will not affect the par value of the Shares. Thus, all shareholders will own the same percentage interest in the Company after the Reverse Split, as they do prior to the Reverse Split.

Following the Reverse Split, the resulting Shares will continue to be traded on the Nasdaq under the stock symbol LEXX but will bear the new CUSIP number 52886N604.

Shareholders of the Company who hold Shares represented by a physical share certificate will need to contact Computershare Trust Company of Canada, as follows, for further information, related costs and procedures before sending any physical share certificates to reflect the Reverse Split adjustment:

PO Box 7023
31 Adelaide Street East
Toronto, ON M5C 2K4
Phone: 1-800-564-6253
Email: [email protected]

About Lexaria Bioscience Corp. & DehydraTECH^™

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^™ has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention ("BIO") in San Diego, CA.

"Lexaria had a full schedule at BIO, meeting with a diverse group of companies ranging from innovative smaller tech-focused firms to multi-billion-dollar global pharmaceutical companies," said Richard Christopher, CEO of Lexaria Bioscience Corp. "We are balancing new exploratory corporate opportunities with existing corporate relationships, with the intent of entering into partnership arrangements. Not a week goes by without discussion with one or more potential partners."

While new corporate relationships require time to identify areas of common interest and capabilities, including but not limited to technologic compatibility, we also continue to advance our pre-existing corporate relationships. While timelines and closure rates are impossible to predict, Lexaria remains optimistic about its prospects.

Of note, most of Lexaria's business discussions are related to the GLP-1 sector and its many applications. Within the GLP-1 sector, Lexaria detected a notable shift in this year's BIO conference to a focus on drug safety and adverse event profiles, given the reality that certain drugs currently under development are approaching practical maximums of weight-loss efficacy. Both in public presentations as well as in our one-on-one meetings, a growing number of pharmaceutical companies are confirming that their focus has shifted towards finding a better balance between weight-loss efficacy, tolerability and safety. The idea that GLP-1 drugs can work effectively at the same time as minimizing unpleasant adverse events is consistent with both Lexaria's mission, and the capabilities of our DehydraTECH^TM technology.

In addition, Lexaria is pleased to report that interest in DehydraTECH technology is expanding once again outside of the GLP-1 industry. Lexaria has recently received renewed incoming corporate interest in the DehydraTECH-CBD and DehydraTECH-nicotine sectors where the Company has conducted extensive previous R&D validating the efficacy of the DehydraTECH technology.

Additional business development information will be made available as appropriate.

About Lexaria Bioscience Corp. & DehydraTECH™

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14^th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's® ("Novo") commercially available Wegovy® tablets, over a 5-week duration (the "Study").

Lexaria is seeking to preserve the superior safety and tolerability profiles evidenced in its previous glucagon-like peptide-1 ("GLP-1") studies such as Human Study #4 (GLP-1-H24-4), combined with pharmacokinetic ("PK") performance that matches or exceeds the Wegovy® tablet control. Previous Lexaria salcaprozate sodium ("SNAC")-inclusive DHT-sema single dose studies such as Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2) evidenced PK performance that matched or exceeded the Rybelsus® control arm and also evidenced noteworthy safety and tolerability profiles.

The results of this Study are expected to be carefully reviewed by the pharmaceutical industry in order to evaluate the possibility of entering into commercial relationships focused on Lexaria's proprietary DehydraTECH™ technology.

The Study is investigating three separate arms to assess safety & tolerability as well as PK properties that will compare SNAC-inclusive, DHT-sema compositions formulated in both tablet and capsule formats to commercially available Wegovy® tablets. The Study is being conducted under fasted pre-dose conditions similar to the advised administration criteria of Novo's oral semaglutide products. The 5-week dosing duration was selected in order to allow for achievement of steady state concentration levels, meaning that the semaglutide blood quantities in each arm will be expected to reach an equilibrium level that balances drug input with natural bodily elimination.

The Study is exploring several new DehydraTECH™ enhancements not previously evaluated, which include but are not limited to the following two main improvements:

(1) First, an oral tablet DHT-sema composition will be used by Lexaria for the first time, as opposed to only the capsule compositions administered in all our previous DehydraTECH™ GLP-1 studies. Novo's Rybelsus® and Wegovy® oral semaglutide medications use specially formulated tablets designed to temporarily adhere to the stomach lining and disintegrate and dissolve releasing agents in a focal manner that aids in optimizing absorption of semaglutide into the human body. For the first time ever, Lexaria has attempted to mimic and integrate certain physical properties of the Rybelsus® and Wegovy® SNAC-inclusive tablet delivery modality into its DHT-sema tablets to follow established industry standards and thereby increase the likelihood of subsequent commercial pharmaceutical relationships.

(2) Second, both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations will be evaluated over a multi-dose, multi-week time period in humans. The five-week dosing duration of the Study is expected to be long enough to reach so-called steady-state, which is when drug concentrations in the body reach a constant concentration. As noted above, Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2), conducted in 2024 and 2025 which incorporated SNAC (but did not use tablets), were limited by single-dose study designs and therefore of much shorter duration.

The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH™

DehydraTECH^TM is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

Potentially Valuable Novel Compositions Being Investigated

Lexaria Also Receives Additional New Granted Patent

KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following update on Animal Study #1 (GLP-1-A26-1) that is evaluating a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").

The Study is on schedule and dosing began on June 10, 2026, as planned. Barring any unforeseen interruptions, Study results are currently expected by early September.

One of the novel objectives of this Study is to evaluate innovative alternative formulations to SNAC (salcaprozate sodium) which is currently in use by Novo Nordisk® with their oral Rybelsus® and Wegovy® tablet products. If Lexaria is able to scientifically evidence novel new formulations with similarity or superiority to SNAC performance enhancements, we may be able to establish valuable new proprietary IP and an industry alternative to SNAC that could be of value within the keenly competitive GLP-1 sector. To this end, Lexaria is pleased to report that we have already filed 3 new patent applications that anticipate our latest technological improvements in this area.

The Study is utilizing Sprague-Dawley rats with 11 separate Study arms evaluating a number of different novel compositions. Blood samples are being taken at multiple timepoints through an 8-24 hour post-dosing period to quantify the pharmacokinetic performance of each composition. In addition, the Study will also measure drug concentrations in the brain since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital.

There will be one reference arm using an existing DHT-sema composition and another reference arm using an existing DHT-CBD composition. Lexaria will leverage the wealth of study data that we have amassed from previous work by utilizing our proprietary historical data and the reference arms as baseline comparators to the current Study results as we search for areas of improvement.

The Study is fully funded from existing corporate resources.

Lexaria is also pleased to report that on June 11, 2026 we received our first Australian patent grant (#2023302884) in our Family #21 - Pharmaceutical Compositions and Methods for Treating Hypertension. This patent represents our 7^th patent in this family with 3 others previously granted in the US, 1 in Europe and 2 in Japan. The term of this patent is until April 25, 2043.

About Lexaria Bioscience Corp. & DehydraTECH™

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

More People Than Ever Taking GLP-1 Drugs for Weight Loss

Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs

KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update.

On June 7^th, Novo Nordisk® ("Novo") announced that over three million Wegovy® pill prescriptions had been filled since its initial launch on January 5, 2026, in what they call "one of the strongest US pharmaceutical launches by volume on record". They also offered the information that 82% of those prescriptions went to people previously untreated with GLP-1 medications, supporting Lexaria's long-held thesis that orally-delivered GLP-1 would greatly expand the marketplace in comparison to injectable delivery.

Just four days earlier, on June 3^rd, Novo announced that Wegovy® pills were being launched in the United Arab Emirates for purposes of weight-loss. Novo further announced, on June 11^th, that Wegovy® had been approved in the United Kingdom as the first daily GLP-1 weight-loss pill in that country, demonstrating the continued expansion around the world of orally-delivered GLP-1 medications specifically indicated for weight loss.

Not to be outdone, in recent weeks Eli Lilly and Company® ("Lilly") announced a series of results from its Phase 3 trials on retatrutide, an investigational drug targeting GLP-1, glucagon, and GIP ("glucose-dependent insulinotropic polypeptide") receptors. In their Phase 3 TRIUMPH-1 study of 2,339 people, retatrutide injected at 12mg once weekly resulted in an average weight loss of 28.3% over an 80-week period. This degree of weight loss was so extensive as to cause 65.3% of people to reach a BMI of under 30, meaning that they no longer met the BMI criteria for obesity.

In that same study, retatrutide reduced knee osteoarthritis pain by 73.1% and moderate-to-severe obstructive sleep apnea severity by up to 60.6% per hour. This broadening of applications of GLP-1 drugs has long been envisioned as an extremely important byproduct of effective weight loss treatments:

"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos," said Ania Jastreboff, M.D., Ph.D., Professor of Medicine & Pediatrics (Endocrinology) at the Yale School of Medicine, Director of the Yale Obesity Research Center (Y-Weight), and lead investigator. "In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea, with many individuals reaching what are classified as healthy-range weight and normal blood sugar levels."

On June 8^th, Lilly released results from its ACHIEVE Phase 3 trials that demonstrated that their daily oral GLP-1 drug, Foundayo® (orforglipron), lowered A1C levels by 2.2% from a baseline of 8.3% to just 6.1%: a reduction of 26.5% over a period of 52 weeks. Foundayo® is being investigated as a potential treatment for all of type 2 diabetes, obstructive sleep apnea, weight management, hypertension, osteoarthritis knee pain, peripheral artery disease, and stress urinary incontinence.

A very large dataset of more than 2 million veterans revealed that GLP-1 drugs offer potentially significant benefits to neurological and behavioral health with reduced risks of addiction to substances such as alcohol, cannabis, stimulants and opioids, as well as a decreased risk of neurocognitive disorders such as Alzheimer's and dementia where they have evidenced reduced inflammation in the brain. Also confirmed in the dataset were earlier discoveries of the drug's potential to lower the risk of heart attack, stroke, high cholesterol, and other cardiovascular conditions. Other studies have pointed to benefits experienced by persons with chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), and arthritis.

It can no longer be a surprise that revenue forecasts for these drugs are surging, as Lexaria earlier noted: TD Cowen® raised their previous 2030 sales forecast of the overall GLP-1 sector from $101 billion to $139 billion, Roots Analysis is forecasting sales of $180 billion by 2035, while UBS Investment Bank® expects 2029 GLP-1 sales to reach $126 billion.

The obesity and diabetes markets continue to be dominated by Lilly and Novo. Naysayers expected the excitement of the popular weight loss drugs to fade but they could not have been more wrong. If anything, the scale of investigation is increasing and new drug possibilities are accelerating - not consolidating. According to IQVIA, more than 193 obesity pipeline assets are in active clinical development with 8 more novel GLP-1 drug approvals expected in the next 4 years.

Effectiveness of these drugs is no longer in question and may be reaching practical limitations when it comes to weight loss (above). The largest opportunity for product improvement is in the area of patient safety. The existing medications in the market today notoriously cause unwanted adverse events ("AEs"), more specifically gastrointestinal ("GI") AEs (nausea, vomiting, diarrhea, and constipation).

To that end, Lexaria is working to position its DehydraTECH™ (also referred to as "DHT") drug delivery technology as not only an improved drug absorption/performance enhancer, but also as a vital enabler of reducing side effects of various GLP-1 drugs. Lexaria continues to advance its DehydraTECH™ pipeline by launching two new animal studies this year on drugs never before tested for compatibility with our technology: retatrutide and amycretin. The following table summarizes the dramatic improvements in GI AEs that Lexaria has realized when testing three (semaglutide, tirzepatide, and liraglutide) of the major GLP-1 drugs on the market today with its DehydraTECH™ technology in an oral format:

* oral dosing was performed after overnight fasting in all instances, except for GLP-1-H24-2 where fed pre-dosing conditions were applied.

** partial/8-week results from 12-week study

With our extensive wholly-owned patent portfolio protecting DehydraTECH™ worldwide, Lexaria continues to take steps to unlock the value of its robust drug delivery platform and continues to discuss business development opportunities with interested commercial partners. As the diabetes control and weight-loss industries continue to focus on GLP-1 and even more advanced drug generations for these and other therapeutic indications, Lexaria remains confident that DehydraTECH™ is valid for utilization with the right commercial partner(s).

About Lexaria Bioscience Corp. & DehydraTECH™

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH^™

KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECH^TM performance as well as potentially stake new intellectual property claims.

Retatrutide is one of Eli Lilly and Company's^® leading next-generation GLP-1 drugs undergoing extensive trials in the weight loss space, where two current Phase 3 studies were recently reported to deliver average weight loss of 28.3% - or 70 pounds - when evaluating patients who stayed on the drug. Unlike the GLP-1 drugs currently on the market, retatrutide is a triple hormone receptor agonist, targeting each of GLP-1, glucagon, and GIP ("glucose-dependent insulinotropic polypeptide"). Retatrutide is currently administered only via weekly injections, whereas Lexaria's Study will examine oral dosing formulated via tablets and capsules.

Weight loss with retatrutide - which has not yet been approved by the FDA - seems to be higher than with any other GLP-1 drug on the market today, with an astonishing 65.3% of participants taking the 12mg dose of retatrutide achieving a BMI ("body mass index") of less than 30, meaning they no longer met the minimum BMI criteria for obesity.

Lexaria's investigation into retatrutide, if successful, would expand DehydraTECH's applicability to prospective triple-agonist weight-loss peptide drugs in late stages of development, that could potentially dominate the future market.

"This is a watershed moment for Lexaria's investigations into GLP-1 drugs," said Richard Christopher, CEO of Lexaria Bioscience. "We have already established the compatibility of our technology with today's leading GLP-1 drugs, but if we are likewise able to demonstrate benefits with the drugs of tomorrow like retatrutide, amycretin and others, then we will begin to show relevance to those drugs that will likely be on the market for the next 10 years or more."

Lexaria's large Study is investigating 18 different study arms to evaluate new and novel DehydraTECH^TM compositions that may be of interest to industry. Blood samples are being taken at multiple timepoints through a 24-hour post-dosing period to quantify the pharmacokinetic ("PK") performance of each composition. The primary goals of this Study are to investigate compatibility of retatrutide and amycretin with Lexaria's DehydraTECH^TM formulation and processing technology, centered around PK performance and tolerability. Retatrutide is owned by Eli Lilly and Company^®, whereas amycretin is owned by Novo Nordisk^®.

As is the case with all GLP-1 drugs on the market today, common side effects of next-generation retatrutide and amycretin GLP-1 drugs include nausea and gastrointestinal issues such as diarrhea and vomiting. With this Study and others planned, Lexaria is attempting to establish that DehydraTECH^TM processing of these drugs may lower the severity and instances of side effects while maintaining or improving efficacy.

This Study will also directly compare pill (tablet) formulations to capsules, to better understand the differences between absorption of the active drugs primarily through either the stomach (pills) or the intestine (capsules). Most oral GLP-1 peptide drugs on the market today rely on pill formulations that are primarily absorbed through the stomach.

As in Animal Study #1 announced on April 15th, this new Study will evaluate alternative formulations to the salcaprozate sodium (SNAC) technology currently incorporated in Novo Nordisk's^® oral Rybelsus^® and Wegovy^® tablet products. The present Study will include but not be limited to compositions using a different delivery enabling compound, sodium caprate, which has itself been shown to influence gastrointestinal absorption.

This is a self-sponsored Lexaria Study that is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH^TM

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH^TM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.